Kristina Masson, Ph.D., MBA, is Co-Founder and EVP, Business Operations at Acrivon Therapeutics, Inc. a publicly traded Boston-based biotech company, and President and CEO of the company´s research subsidiary Acrivon AB located in Medicon Village, Sweden. Here she has established all infrastructure, heads all operations, and runs the phospho-proteomic discovery and early drug programs for the company’s proprietary AP3 platform. In 2016, she founded and operated OncoSignature AB., a small biotech company focused on identifying predictive biomarkers for clinical-stage cancer therapeutics for U.S. companies. OncoSignature’s business was subsequently acquired by Acrivon AB. Prior to that, she was a Principal Scientist at Merrimack Pharmaceuticals, Cambridge, MA where she co-led, managed, and participated in cross-functional teams in both preclinical and clinical-stage therapeutic antibody programs, designing projects to identify predictive biomarkers, combination strategies and resistance mechanisms. Before joining Merrimack Pharmaceuticals, Kristina was a Post-Doctoral Fellow in the Golub lab at the Broad Institute of MIT and Harvard, developing assays for novel therapeutics and automated high-throughput drug screening approaches centered around synthetic lethality in cancer. Kristina holds a Ph.D. in Molecular Signaling and a M.Sc. in Biomedicine from Lund University, Sweden, and she received her Executive MBA from the Massachusetts Institute of Technology Sloan School of Management.